Physicochemical properties of ferumoxytol, a new intravenous iron preparation

European Journal of Clinical Investigation

Volumn 39, Issue 6, 2009, Pages 489-496

  Balakrishnan, V S ^a,b   Rao, M ^b   Kausz, A T ^b,c   Brenner, L ^c,d   Pereira, B J G ^c   Frigo, T B ^c   Lewis, J M ^c  

^a Division of Nephrology   (United States)

^b TUFTS MEDICAL CENTER   (United States)

^c AMAG PHARMACEUTICALS INC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bleomycin detectable iron; Ferumoxytol; Free iron; Molecular weight; Osmolality

Indexed keywords

FERRIC GLUCONATE; FERRIC HYDROXIDE SUCROSE; FERUMOXYTOL; IRON DEXTRAN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; IRON BLOOD LEVEL; IRON KINETICS; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; SERUM OSMOLALITY;

ANEMIA; ANIMALS; DRUG ADMINISTRATION SCHEDULE; FERROSOFERRIC OXIDE; HUMANS; INFUSIONS, INTRAVENOUS; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MOLECULAR WEIGHT; OXIDATIVE STRESS; RATS;

EID: 65549161973     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02130.x     Document Type: Article

References (29)

1. Identifying patients and initiating evaluation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006 47 : S1 146.
2. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis 2001 38 : 988 91. (Pubitemid 33022176)
3. Bastani B, Jain A, Pandurangan G. Incidence of side-effects associated with high-dose ferric gluconate in patients with severe chronic renal failure. Nephrology (Carlton) 2003 8 : 8 10. (Pubitemid 36237944)
4. Parkkinen J, von Borsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000 15 : 1827 34.
5. Michelis R, Gery R, Sela S, Shurtz-Swirski R, Grinberg N, Snitkovski T et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003 18 : 924 30. (Pubitemid 36592534)
6. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008 19 : 1599 605.
7. Gutteridge JM, Quinlan GJ, Evans TW. Transient iron overload with bleomycin detectable iron in the plasma of patients with adult respiratory distress syndrome. Thorax 1994 49 : 707 10. (Pubitemid 24219152)
8. Burkitt MJ, Milne L, Raafat A. A simple, highly sensitive and improved method for the measurement of bleomycin-detectable iron: the 'catalytic iron index' and its value in the assessment of iron status in haemochromatosis. Clin Sci 2001 100 : 239 47. (Pubitemid 32215994)
9. Kudasheva DS, Lai J, Ulman A, Cowman MK. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem 2004 98 : 1757 69. (Pubitemid 39456424)
10. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S et al. Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 1999 104 : 296 302. (Pubitemid 29083337)
11. Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 2001 37 : 879 83. (Pubitemid 32475744)
12. Beshara S, Sorensen J, Lubberink M, Tolmachev V, Langstrom B, Antoni G et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol 2003 120 : 853 9. (Pubitemid 36315111)
13. Kanakakorn K, Cavill I, Jacobs A. The metabolism of intravenously administered iron-dextran. Br J Haematol 1973 25 : 637 43.
14. Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002 40 : 90 103. (Pubitemid 34701216)
15. Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest 2002 32 (Suppl. 1 42 9. (Pubitemid 41704987)
16. Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant 2004 19 : 561 5. (Pubitemid 38263113)
17. Zanen AC, Adriaansen HJ, van Bommel EFH, Posthuma R, de Jong GM. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transplant 1996 11 : 820 4. (Pubitemid 26148673)
18. Roob JM, Khoschsorur G, Tiran A, Horina JH, Holzer H, Winklhofer-Roob BM. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000 11 : 539 49. (Pubitemid 30115084)
19. Lawrence R. Development and comparison of iron dextran products. PDA J Pharm Sci Technol 1998 52 : 190 7. (Pubitemid 28548896)
20. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung 1992 42 : 1439 52. (Pubitemid 23007362)
21. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004 15 : S93 8. (Pubitemid 39578822)
22. Mossey RT, Sondheimer J. Listeriosis in patients with long-term hemodialysis and transfusional iron overload. Am J Med 1985 79 : 397 400. (Pubitemid 15232517)
23. Sengoelge G, Kletzmayr J, Ferrara I, Perschl A, Horl WH, Sunder-Plassman G. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 2003 14 : 2639 44. (Pubitemid 37169351)
24. Guo D, Jaber BL, Lee S, Perianayagam MC, King AJ, Pereira BJ et al. Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 2002 58 : 134 42.
25. Salahudeen AK, Oliver B, Bower JD, Roberts LJ. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001 60 : 1525 31. (Pubitemid 32960048)
26. Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics 2001 107 : 78 85. (Pubitemid 32055419)
27. Rooyakkers TM, Stroes ES, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002 32 (Suppl. 1 9 16. (Pubitemid 41704982)
28. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999 14 : 2680 7. (Pubitemid 32208386)
29. Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002 106 : 2212 7. (Pubitemid 35222215)